Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus.

Atcheson E, Li W, Bliss CM, Chinnakannan S, Heim K, Sharpe H, Hutchings C, Dietrich I, Nguyen D, Kapoor A, Jarvis MA, Klenerman P, Barnes E, Simmonds P.

Hepatology. 2019 Aug 10. doi: 10.1002/hep.30894. [Epub ahead of print]

PMID:
31400152
2.

Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age.

Kornstein SG, Bliss C, Kando J, Madhoo M.

J Clin Psychiatry. 2019 Feb 26;80(2). pii: 18m12378. doi: 10.4088/JCP.18m12378.

3.

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.

Hartnell F, Brown A, Capone S, Kopycinski J, Bliss C, Makvandi-Nejad S, Swadling L, Ghaffari E, Cicconi P, Del Sorbo M, Sbrocchi R, Esposito I, Vassilev V, Marriott P, Gardiner CM, Bannan C, Bergin C, Hoffmann M, Turner B, Nicosia A, Folgori A, Hanke T, Barnes E, Dorrell L.

Front Immunol. 2019 Jan 18;9:3175. doi: 10.3389/fimmu.2018.03175. eCollection 2018.

4.

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.

Tiono AB, Nébié I, Anagnostou N, Coulibaly AS, Bowyer G, Lam E, Bougouma EC, Ouedraogo A, Yaro JBB, Barry A, Roberts R, Rampling T, Bliss C, Hodgson S, Lawrie A, Ouedraogo A, Imoukhuede EB, Ewer KJ, Viebig NK, Diarra A, Leroy O, Bejon P, Hill AVS, Sirima SB.

PLoS One. 2018 Dec 12;13(12):e0208328. doi: 10.1371/journal.pone.0208328. eCollection 2018.

5.

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP.

Rampling T, Ewer KJ, Bowyer G, Edwards NJ, Wright D, Sridhar S, Payne R, Powlson J, Bliss C, Venkatraman N, Poulton ID, de Graaf H, Gbesemete D, Grobbelaar A, Davies H, Roberts R, Angus B, Ivinson K, Weltzin R, Rajkumar BY, Wille-Reece U, Lee C, Ockenhouse C, Sinden RE, Gerry SC, Lawrie AM, Vekemans J, Morelle D, Lievens M, Ballou RW, Lewis DJM, Cooke GS, Faust SN, Gilbert S, Hill AVS.

NPJ Vaccines. 2018 Oct 9;3:49. doi: 10.1038/s41541-018-0084-2. eCollection 2018.

7.

Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.

Huss M, McBurnett K, Cutler AJ, Hervás A, Bliss C, Gao J, Dirks B, Newcorn JH.

Eur Neuropsychopharmacol. 2019 Mar;29(3):432-443. doi: 10.1016/j.euroneuro.2018.05.012. Epub 2018 Jul 29.

9.

Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies.

Citrome L, Kando JC, Bliss C.

Neuropsychiatr Dis Treat. 2018 Feb 15;14:537-546. doi: 10.2147/NDT.S158395. eCollection 2018.

10.

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.

Bliss CM, Bowyer G, Anagnostou NA, Havelock T, Snudden CM, Davies H, de Cassan SC, Grobbelaar A, Lawrie AM, Venkatraman N, Poulton ID, Roberts R, Mange PB, Choudhary P, Faust SN, Colloca S, Gilbert SC, Nicosia A, Hill AVS, Ewer KJ.

Sci Rep. 2018 Feb 21;8(1):3390. doi: 10.1038/s41598-018-21630-4.

11.

Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate.

Coghill DR, Banaschewski T, Bliss C, Robertson B, Zuddas A.

CNS Drugs. 2018 Jan;32(1):85-95. doi: 10.1007/s40263-017-0487-z.

12.

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial.

Mensah VA, Roetynck S, Kanteh EK, Bowyer G, Ndaw A, Oko F, Bliss CM, Jagne YJ, Cortese R, Nicosia A, Roberts R, D'Alessio F, Leroy O, Faye B, Kampmann B, Cisse B, Bojang K, Gerry S, Viebig NK, Lawrie AM, Clarke E, Imoukhuede EB, Ewer KJ, Hill AVS, Afolabi MO.

Front Immunol. 2017 Nov 20;8:1551. doi: 10.3389/fimmu.2017.01551. eCollection 2017.

13.

Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.

Venkatraman N, Anagnostou N, Bliss C, Bowyer G, Wright D, Lövgren-Bengtsson K, Roberts R, Poulton I, Lawrie A, Ewer K, V S Hill A.

Vaccine. 2017 Oct 27;35(45):6208-6217. doi: 10.1016/j.vaccine.2017.09.028. Epub 2017 Sep 21.

PMID:
28941620
14.

Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD.

Coghill DR, Joseph A, Sikirica V, Kosinski M, Bliss C, Huss M.

J Atten Disord. 2017 Aug 1:1087054717723984. doi: 10.1177/1087054717723984. [Epub ahead of print]

15.

Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study.

Siebers N, Palmer M, Silberg DG, Jennings L, Bliss C, Martin PT.

Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):91-101. doi: 10.1007/s13318-017-0429-7.

16.

Embolized Stems Recover Overnight in Zea mays: The Role of Soil Water, Root Pressure, and Nighttime Transpiration.

Gleason SM, Wiggans DR, Bliss CA, Young JS, Cooper M, Willi KR, Comas LH.

Front Plant Sci. 2017 Apr 28;8:662. doi: 10.3389/fpls.2017.00662. eCollection 2017.

17.

Metabolic reprogramming of the premalignant colonic mucosa is an early event in carcinogenesis.

Cruz MD, Ledbetter S, Chowdhury S, Tiwari AK, Momi N, Wali RK, Bliss C, Huang C, Lichtenstein D, Bhattacharya S, Varma-Wilson A, Backman V, Roy HK.

Oncotarget. 2017 Mar 28;8(13):20543-20557. doi: 10.18632/oncotarget.16129.

18.

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants.

Bliss CM, Drammeh A, Bowyer G, Sanou GS, Jagne YJ, Ouedraogo O, Edwards NJ, Tarama C, Ouedraogo N, Ouedraogo M, Njie-Jobe J, Diarra A, Afolabi MO, Tiono AB, Yaro JB, Adetifa UJ, Hodgson SH, Anagnostou NA, Roberts R, Duncan CJ, Cortese R, Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampmann B, Imoukhuede EB, Sirima SB, Bojang K, Hill AV, Nébié I, Ewer KJ.

Mol Ther. 2017 Feb 1;25(2):547-559. doi: 10.1016/j.ymthe.2016.11.003.

19.

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.

Mensah VA, Gueye A, Ndiaye M, Edwards NJ, Wright D, Anagnostou NA, Syll M, Ndaw A, Abiola A, Bliss C, Gomis JF, Petersen I, Ogwang C, Dieye T, Viebig NK, Lawrie AM, Roberts R, Nicosia A, Faye B, Gaye O, Leroy O, Imoukhuede EB, Ewer KJ, Bejon P, Hill AV, Cisse B; MVVC group.

PLoS One. 2016 Dec 15;11(12):e0167951. doi: 10.1371/journal.pone.0167951. eCollection 2016.

20.
21.
22.

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.

Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, Steenbergen JN, Hershberger E, Umeh O, Kaye KS.

J Antimicrob Chemother. 2017 Jan;72(1):268-272. Epub 2016 Oct 5.

PMID:
27707990
23.

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.

Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, Payne RO, Venkatraman N, de Barra E, Snudden CM, Poulton ID, de Graaf H, Sukhtankar P, Roberts R, Ivinson K, Weltzin R, Rajkumar BY, Wille-Reece U, Lee CK, Ockenhouse CF, Sinden RE, Gerry S, Lawrie AM, Vekemans J, Morelle D, Lievens M, Ballou RW, Cooke GS, Faust SN, Gilbert S, Hill AV.

J Infect Dis. 2016 Sep 1;214(5):772-81. doi: 10.1093/infdis/jiw244. Epub 2016 Jun 15.

24.

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.

Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nébié I, Bliss C, Hodgson SH, Anagnostou NA, Sanou GS, Jagne YJ, Ouedraogo O, Tamara C, Ouedraogo N, Ouedraogo M, Njie-Jobe J, Diarra A, Duncan CJ, Cortese R, Nicosia A, Roberts R, Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampman B, Bejon P, Imoukhuede EB, Ewer KJ, Hill AV, Bojang K, Sirima SB.

Mol Ther. 2016 Aug;24(8):1470-7. doi: 10.1038/mt.2016.83. Epub 2016 Apr 25.

25.

Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.

Huntington JA, Sakoulas G, Umeh O, Cloutier DJ, Steenbergen JN, Bliss C, Goldstein EJ.

J Antimicrob Chemother. 2016 Jul;71(7):2014-21. doi: 10.1093/jac/dkw053. Epub 2016 Mar 18.

PMID:
26994090
26.

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.

Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, Bliss C, Hodgson SH, Njuguna P, Viebig NK, Nicosia A, Gitau E, Douglas S, Illingworth J, Marsh K, Lawrie A, Imoukhuede EB, Ewer K, Urban BC, Hill AVS, Bejon P; MVVC group.

Sci Transl Med. 2015 May 6;7(286):286re5. doi: 10.1126/scitranslmed.aaa2373.

27.

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.

Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV.

N Engl J Med. 2016 Apr 28;374(17):1635-46. doi: 10.1056/NEJMoa1411627. Epub 2015 Jan 28.

28.

The long-term dynamics of Campylobacter colonizing a free-range broiler breeder flock: an observational study.

Colles FM, McCarthy ND, Bliss CM, Layton R, Maiden MC.

Environ Microbiol. 2015 Apr;17(4):938-46. doi: 10.1111/1462-2920.12415. Epub 2014 Mar 11.

29.

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.

de Barra E, Hodgson SH, Ewer KJ, Bliss CM, Hennigan K, Collins A, Berrie E, Lawrie AM, Gilbert SC, Nicosia A, McConkey SJ, Hill AV.

PLoS One. 2014 Dec 18;9(12):e115161. doi: 10.1371/journal.pone.0115161. eCollection 2014.

30.

Estimation of global network statistics from incomplete data.

Bliss CA, Danforth CM, Dodds PS.

PLoS One. 2014 Oct 22;9(10):e108471. doi: 10.1371/journal.pone.0108471. eCollection 2014.

31.

Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.

Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, de Barra E, Havelock T, Bowyer G, Poulton ID, de Cassan S, Longley R, Illingworth JJ, Douglas AD, Mange PB, Collins KA, Roberts R, Gerry S, Berrie E, Moyle S, Colloca S, Cortese R, Sinden RE, Gilbert SC, Bejon P, Lawrie AM, Nicosia A, Faust SN, Hill AV.

J Infect Dis. 2015 Apr 1;211(7):1076-86. doi: 10.1093/infdis/jiu579. Epub 2014 Oct 21.

32.

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.

Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, de Cassan SC, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Osier FH, Hodgson SH, Duncan CJ, O'Hara GA, Long CA, Hill AV, Draper SJ.

PLoS One. 2014 Sep 25;9(9):e107903. doi: 10.1371/journal.pone.0107903. eCollection 2014.

33.

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, Ogwang C, Afolabi MO, Bowyer G, Collins KA, Edwards N, Hodgson SH, Duncan CJ, Spencer AJ, Knight MG, Drammeh A, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Soipei P, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Chilengi R, Bojang K, Flanagan KL, Hill AV, Urban BC, Ewer KJ.

Mol Ther. 2014 Nov;22(11):1992-2003. doi: 10.1038/mt.2014.109. Epub 2014 Jun 16.

34.

Comparison of high-volume air sampling equipment for viral aerosol sampling during emergency response.

Cooper C, Slagley J, Lohaus J Jr, Escamilla E, Bliss C, Semler D, Felker D, Smith D, Ott D.

J Emerg Manag. 2014 Mar-Apr;12(2):161-70. doi: 10.5055/jem.2014.0170.

PMID:
24828912
35.

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.

Elias SC, Choudhary P, de Cassan SC, Biswas S, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Hodgson SH, Duncan CJ, Hill AV, Draper SJ.

Immunology. 2014 Apr;141(4):628-44. doi: 10.1111/imm.12226.

36.

Ocular findings and reference values for selected ophthalmic diagnostic tests in the macaroni penguin (Eudyptes chrysolophus) and southern rockhopper penguin (Eudyptes chrysocome).

Bliss CD, Aquino S, Woodhouse S.

Vet Ophthalmol. 2015 Jan;18 Suppl 1:86-93. doi: 10.1111/vop.12123. Epub 2013 Nov 18.

PMID:
24238103
38.

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, Duncan CJ, Collins KA, Garcia Knight MA, Kimani E, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Spencer AJ, Soipei P, Mueller J, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Gantlett K, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Urban BC, Flanagan KL, Ewer KJ, Chilengi R, Hill AV, Bojang K.

PLoS One. 2013;8(3):e57726. doi: 10.1371/journal.pone.0057726. Epub 2013 Mar 19.

39.

Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.

Elias SC, Collins KA, Halstead FD, Choudhary P, Bliss CM, Ewer KJ, Sheehy SH, Duncan CJ, Biswas S, Hill AV, Draper SJ.

J Immunol. 2013 Feb 1;190(3):1135-47. doi: 10.4049/jimmunol.1201455. Epub 2013 Jan 4.

40.

Predictors of active injection drug use in a cohort of patients infected with hepatitis C virus.

Reed C, Bliss C, Stuver SO, Heeren T, Tumilty S, Horsburgh CR Jr, Samet JH, Cotton DJ.

Am J Public Health. 2013 Jan;103(1):105-11. doi: 10.2105/AJPH.2012.300819. Epub 2012 Nov 15.

41.

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.

Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, Ewer KJ, Havelock T, Mahungu T, Bliss CM, Miura K, Poulton ID, Lillie PJ, Antrobus RD, Berrie E, Moyle S, Gantlett K, Colloca S, Cortese R, Long CA, Sinden RE, Gilbert SC, Lawrie AM, Doherty T, Faust SN, Nicosia A, Hill AV, Draper SJ.

Mol Ther. 2012 Dec;20(12):2355-68. doi: 10.1038/mt.2012.223. Epub 2012 Oct 23.

42.

Long-term follow-up after voluntary human immunodeficiency virus/sexually transmitted infection counseling, point-of-service testing, and referral to substance abuse treatment from the emergency department.

Bernstein E, Heeren T, Winter M, Ashong D, Bliss C, Madico G, Ayalew B, Bernstein J.

Acad Emerg Med. 2012 Apr;19(4):386-95. doi: 10.1111/j.1553-2712.2012.01314.x.

43.

Acceptance of interferon-gamma release assay by a high-risk urban cohort.

O'Donnell MR, Coe A, Bliss C, Lee D, Tumilty S, Skolnik PR, Horsburgh CR Jr, Cotton D, Saukkonen J.

Int J Tuberc Lung Dis. 2011 Oct;15(10):1334-9. doi: 10.5588/ijtld.11.0029.

PMID:
22283891
44.

Ribosomal multilocus sequence typing: universal characterization of bacteria from domain to strain.

Jolley KA, Bliss CM, Bennett JS, Bratcher HB, Brehony C, Colles FM, Wimalarathna H, Harrison OB, Sheppard SK, Cody AJ, Maiden MC.

Microbiology. 2012 Apr;158(Pt 4):1005-15. doi: 10.1099/mic.0.055459-0. Epub 2012 Jan 27.

45.

The impact of a brief motivational intervention on unprotected sex and sex while high among drug-positive emergency department patients who receive STI/HIV VC/T and drug treatment referral as standard of care.

Bernstein E, Ashong D, Heeren T, Winter M, Bliss C, Madico G, Bernstein J.

AIDS Behav. 2012 Jul;16(5):1203-16. doi: 10.1007/s10461-012-0134-0.

PMID:
22261830
46.

Positivity of the English language.

Kloumann IM, Danforth CM, Harris KD, Bliss CA, Dodds PS.

PLoS One. 2012;7(1):e29484. doi: 10.1371/journal.pone.0029484. Epub 2012 Jan 11.

47.

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.

Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O'Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A.

Sci Transl Med. 2012 Jan 4;4(115):115ra2. doi: 10.1126/scitranslmed.3002925.

48.

Temporal patterns of happiness and information in a global social network: hedonometrics and Twitter.

Dodds PS, Harris KD, Kloumann IM, Bliss CA, Danforth CM.

PLoS One. 2011;6(12):e26752. doi: 10.1371/journal.pone.0026752. Epub 2011 Dec 7.

49.

Effects of aggressive versus moderate glycemic control on clinical outcomes in diabetic coronary artery bypass graft patients.

Lazar HL, McDonnell MM, Chipkin S, Fitzgerald C, Bliss C, Cabral H.

Ann Surg. 2011 Sep;254(3):458-63; discussion 463-4. doi: 10.1097/SLA.0b013e31822c5d78.

PMID:
21865944
50.

Hangover sensitivity after controlled alcohol administration as predictor of post-college drinking.

Rohsenow DJ, Howland J, Winter M, Bliss CA, Littlefield CA, Heeren TC, Calise TV.

J Abnorm Psychol. 2012 Feb;121(1):270-5. doi: 10.1037/a0024706. Epub 2011 Aug 22.

Supplemental Content

Support Center